Clinical Trial Update: CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial evaluating comprehensive phenotypic characterization of patients with scleroderma-associated interstitial lung disease and pulmonary hyp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Pulmonary Hypertension
• Systemic Sclerosis

Snippet

Sponsor: Franz Rischard, DO | Conditions: Interstitial Lung Disease, Scleroderma | Phase 2, Phase 3 | Status: WITHDRAWN